May 12, 2021
TORONTO — A Canadian drugmaker has posted promising Phase 1 trial results for its own COVID-19 vaccine, but is threatening to move its future trials and production out of the country if it doesn’t receive further support from the federal government.
On Wednesday, Calgary-based Providence Therapeutics released results from its Phase 1 trials of 60 participants aged 18-64 that show “strong virus neutralization capability” with no serious side-effects reported, according to a news release.
Participants in the Phase 1 trial were given either a placebo or Providence’s vaccine in one of three dose sizes. After 28 days, participants given any of the vaccine sizes showed COVID-19 antibodies, while all doses showed 100 per cent COVID-19 “blocking activity” after 42 days.